SCHEMBL6801095

SCHEMBL6801095

O=c1nc2n(c3ccccc13)CC[C@H](CBr)S2

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 3/20 0.40
SMARCA4 P51532 6/20 0.39
PBRM1 Q86U86 3/20 0.39
MAPT P10636 3/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.34
RCE1 Q9Y256 1/20 0.34
ACHE P22303 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
BCHE P06276 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795854 0.87 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6801223 0.87 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6796798 0.87 KDM4E (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6796794 0.87 KDM4E (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6796804 0.87 KDM4E (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL7008166 0.80 HPGD (0.43) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6801836 0.76 HPGD (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6801833 0.76 HPGD (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6801830 0.76 HPGD (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL6299773 0.72 ALDH1A1 (0.67) ALDH1A1MEN1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044013-A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) 2004-03-04 US disclosed
EP-1349842-A1 1-DIMERCAPTOALKYLQUINAZOLIN-2,4(1H,3H)-DIONES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS IBFB GmbH Privates Institut für biomedizinische Forschung und Beratung (DE) 2003-10-08 EP disclosed
WO-2002055507-A1 1-DIMERCAPTOALKYLQUINAZOLIN-2,4(1H,3H)-DIONES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS IBFB GMBH PRIVATES INSTITUT FÜR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044013-A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors MMP2, MMP3, MMP1 ALDH1A1 517/4885MEN1 3691/4885KMT2A 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.